Order Article Reprints

Harada Y, Shimada K, Harada SJ, Sato T, Kubota Y, Yamashita M. Iodine-123 β-methyl-P-iodophenyl-pentadecanoic Acid (¹²³I-BMIPP) Myocardial Scintigraphy for Breast Cancer Patients and Possible Early Signs of Cancer-Therapeutics-Related Cardiac Dysfunction (CTRCD). Journal of Imaging. 2022; 8(11):296. https://doi.org/10.3390/jimaging8110296

Harada, Yuko, Kyosuke Shimada, Satoshi John Harada, Tomomi Sato, Yukino Kubota, and Miyoko Yamashita. 2022. "Iodine-123 β-methyl-P-iodophenyl-pentadecanoic Acid (¹²³I-BMIPP) Myocardial Scintigraphy for Breast Cancer Patients and Possible Early Signs of Cancer-Therapeutics-Related Cardiac Dysfunction (CTRCD)" Journal of Imaging 8, no. 11: 296. https://doi.org/10.3390/jimaging8110296

Harada, Y., Shimada, K., Harada, S. J., Sato, T., Kubota, Y., & Yamashita, M. (2022). Iodine-123 β-methyl-P-iodophenyl-pentadecanoic Acid (¹²³I-BMIPP) Myocardial Scintigraphy for Breast Cancer Patients and Possible Early Signs of Cancer-Therapeutics-Related Cardiac Dysfunction (CTRCD). Journal of Imaging, 8(11), 296. https://doi.org/10.3390/jimaging8110296